Low-Tech Breast and Cervical Cancer Screening Studied in India

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

NEW YORK-A randomized trial enrolling 150,000 women and funded by the US National Cancer Institute is underway in India to screen for breast and cervical cancer using simple methods.

NEW YORK—A randomized trial enrolling 150,000 women and funded by the US National Cancer Institute is underway in India to screen for breast and cervical cancer using simple methods.

“Mammography is a very fine tool, but most of the developing world cannot afford mammography, so we have to devise simple techniques,” said Indraneel Mittra, MBBS, PhD, professor of medicine and chief of the Surgical Breast Service, Tata Memorial Hospital, Bombay. He spoke at the International Breast Cancer Roundtable, sponsored by the American-Italian Cancer Foundation and the Komen Breast Cancer Foundation.

Instead, the Indian trial depends on physical examinations performed by trained health workers. “These are women educated to the level of high school,” Professor Mittra said. “You can’t have doctors go out into the community and examine thousands of women.”

The health workers provide instruction in cancer awareness along with printed materials to all women in the study. For the control group, this is the only intervention. Clinical breast examinations are performed on those in the study group, and the health workers teach them breast self-examination.

The health workers also screen all women randomized to the study group for cervical cancer. “We’re not using the Pap smear,” he said. “The Pap smear sounds simple, but it requires many trained technicians and cytopathologists.” Instead, the health workers do a visual inspection of the cervix after applying a 4% acetic acid solution.

In this study, four rounds of screening intervention will be given every 18 months. The final endpoint is a reduction in mortality from breast and cervical cancer.

The incidence of breast cancer is rising in every country in the world, “but faster in the developing countries,” Professor Mittra observed. Among the factors he cited for this surge is women delaying childbirth because of working outside the home. Another factor affecting all types of cancer, he indicated, is increased longevity with the control of infectious diseases.

“In India, it is estimated that life expectancy between 1995 and 2025 will increase by 9 years,” he said. “This will increase the incidence of cancer by 300%.”

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content